Cigna to buy Express Scripts for $67 billion

Print Friendly, PDF & Email

BLOOMFIELD, Conn. — Continuing cross-segment consolidation in the health care arena, health insurer Cigna Corp. plans to acquire pharmacy benefits manager Express Scripts in a $67 billion cash and stock deal.

The companies said Thursday that, under the Cigna-Express Scripts merger agreement, Cigna will pay Express Scripts shareholders $48.75 in cash and 0.2434 shares of stock of the combined company per Express Scripts share, or a total of $54 billion. The consideration represents a 31% premium to Express Scripts’ closing share price of $73.42 on March 7. Cigna also has agreed to assume about $15 billion of Express Scripts’ debt.

When the Cigna-Express Scripts merger transaction is completed, Cigna shareholders will own about 64% of the combined company and Express Scripts shareholders will own approximately 36%.

“Cigna’s acquisition of Express Scripts brings together two complementary customer-centric services companies, well-positioned to drive greater quality and affordability for customers,” Cigna president and chief executive officer David Cordani said in a statement. “This combination accelerates Cigna’s enterprise mission of improving the health, well-being and sense of security of those we serve, and in turn, expanding the breadth of services for our customers, partners, clients, health plans and communities. Together, we will create an expanded portfolio of health services, delivering greater consumer choice, closer alignment between the customer and health care provider, and more personalized value. This combination will create significant benefits to society and differentiated shareholder value.”

Plans call for the merged company to be called Cigna and be based in Bloomfield, Conn., where Cigna now has its headquarters. Express Scripts will maintain its current headquarters in St. Louis.

Cordani is slated to served as president and CEO of the combined company, and Express Scripts president and CEO Tim Wentworth will take the role of president of Express Scripts.

“Together, our two organizations will help make the healthiest choices the easiest choices, putting health and pharmacy services within reach of everyone we serve,” Wentworth said in a statement. “Adding our company’s leadership in pharmacy and medical benefit management, technology-powered clinical solutions, and specialized patient care model to Cigna’s track record of delivering value through innovation, we are positioned to transform health care. We will continue to have a distinct focus at Express Scripts and eviCore on partnering with health plans and, together, build tailored solutions for health plans and their members. Importantly, this agreement is a testament to the work of our team and their resolute focus on providing the best care to patients, and the most value to clients.”

The Cigna and Express Scripts boards of directors have approved the transaction. For the combined company, the board will be expanded to 13 directors, including four independent members of the Express Scripts board.

Cigna and Express Scripts will operate as independent companies until the transaction closes, which is expected by Dec. 31, pending shareholder and regulatory approval and other customary closing conditions.



Comments are closed.